Discovery and preclinical characterization of [18F]PI-2620, a next-generation tau PET tracer for the assessment of tau pathology in Alzheimer’s disease and other tauopathies

• DOI: 10.1007/s00259-019-04397-2
• Publication Date: 2019-07-01T05:02:32Z
• Authors: Heiko Kroth; Felix Oden; Jerome Molette; Hanno Schieferstein; Francesca Capotosti; Andre Mueller; Mathias Berndt; Heribert Schmitt-...; Vincent Darmency; Emanuele Gabellieri; Cédric Boudou; Tanja Juergens; Yvan Varisco; Efthymia Vokali; David T. Hickman; Gilles Tamagnan; Andrea Pfeifer; Ludger Dinkelborg; Andreas Muhs; Andrew Stephens
• Keywords: Tau Pathology; Tauopathy; Corticobasal degeneration; Tau protein

Tau deposition is a key pathological feature of Alzheimer's disease (AD) and other neurodegenerative disorders. The spreading tau neurofibrillary tangles across defined brain regions corresponds to the observed level cognitive decline in AD. Positron-emission tomography (PET) has proved be an important tool for detection amyloid-beta (Aβ) aggregates brain, currently being explored misfolded AD non-AD tauopathies. Several PET tracers targeting deposits have been discovered tested humans. Limitations reported, especially regarding their selectivity.